AC IMMUNE SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.35 USD | +2.62% |
|
-0.42% | -53.00% |
| Mar. 15 | AC Immune Files $350 Million Mixed Shelf | MT |
| Mar. 14 | AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 590.5 | 351.1 | 423 | 145.7 | 415.5 | 202 | - | - |
| Enterprise Value (EV) 1 | 590.5 | 351.1 | 423 | 145.7 | 415.5 | 155.3 | 201.6 | 279.7 |
| P/E ratio | 12.9 x | -5.32 x | -4.65 x | -2.22 x | -6.57 x | -3.26 x | -10.1 x | -8.92 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 5.32 x | 22.8 x | - | 37 x | 28.1 x | 24.3 x | 3.31 x | 3.05 x |
| EV / Revenue | 5.32 x | 22.8 x | - | 37 x | 28.1 x | 18.6 x | 3.3 x | 4.23 x |
| EV / EBITDA | 12.9 x | -5.92 x | -5.52 x | -2.13 x | -8.08 x | -2.14 x | -3.99 x | -3.54 x |
| EV / FCF | - | -5.73 x | -6.19 x | -1.95 x | -6.79 x | -2.36 x | 6.7 x | 5 x |
| FCF Yield | - | -17.4% | -16.2% | -51.3% | -14.7% | -42.3% | 14.9% | 20% |
| Price to Book | 2.17 x | 1.53 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 71,662 | 76,741 | 93,691 | 77,257 | 98,801 | 93,954 | - | - |
| Reference price 2 | 8.240 | 4.575 | 4.515 | 1.886 | 4.205 | 2.150 | 2.150 | 2.150 |
| Announcement Date | 3/30/20 | 3/23/21 | 3/22/22 | 3/16/23 | 3/14/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 111 | 15.43 | - | 3.935 | 14.8 | 8.325 | 61.1 | 66.17 |
| EBITDA 1 | 45.81 | -59.29 | -76.6 | -68.49 | -51.41 | -72.5 | -50.5 | -79.1 |
| EBIT 1 | 44.54 | -61.26 | -79.01 | -70.85 | -53.62 | -67.84 | -5.359 | -4.026 |
| Operating Margin | 40.11% | -396.99% | - | -1,800.43% | -362.3% | -814.83% | -8.77% | -6.08% |
| Earnings before Tax (EBT) 1 | 45.44 | -61.92 | -72.99 | -70.74 | -54.22 | -67.61 | -5.259 | -5.976 |
| Net income 1 | 45.44 | -61.92 | -73 | -70.75 | -54.23 | -66.6 | -23.83 | -26.75 |
| Net margin | 40.93% | -401.28% | - | -1,798.04% | -366.41% | -799.94% | -39% | -40.42% |
| EPS 2 | 0.6400 | -0.8600 | -0.9700 | -0.8500 | -0.6400 | -0.6590 | -0.2127 | -0.2410 |
| Free Cash Flow 1 | - | -61.22 | -68.32 | -74.81 | -61.21 | -65.71 | 30.1 | 55.92 |
| FCF margin | - | -396.75% | - | -1,901.07% | -413.55% | -789.27% | 49.25% | 84.52% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 3/23/21 | 3/22/22 | 3/16/23 | 3/14/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | 3.934 | 0.001 | - | - | - | 14.8 | 5.325 | 0.5 | 0.5 | 3.5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.28 | -22.79 | -18.83 | -19.86 | -13.46 | -18.7 | -17.57 | -17.05 | -15.47 | -3.541 | -10.79 | -18.52 | -18.84 | -18.98 |
| Operating Margin | - | - | - | - | -342.22% | -1,869,500% | - | - | - | -23.92% | -202.68% | -3,703.95% | -3,768.1% | -542.43% |
| Earnings before Tax (EBT) 1 | -15.92 | -21.27 | -18.84 | -19.64 | -13.51 | -18.74 | -17.51 | -16.83 | -15.14 | -4.743 | -11.04 | -18.34 | -18.67 | -18.86 |
| Net income 1 | -15.92 | -21.28 | -18.85 | -19.64 | -13.52 | -18.75 | -17.51 | -16.83 | -15.14 | -4.744 | -13.09 | -18.13 | -18.41 | -16.57 |
| Net margin | - | - | - | - | -343.57% | -1,874,600% | - | - | - | -32.05% | -245.82% | -3,625.61% | -3,681.71% | -473.47% |
| EPS 2 | -0.2200 | -0.2600 | -0.2300 | -0.2300 | -0.1600 | -0.2300 | -0.2100 | -0.2000 | -0.1800 | -0.0500 | -0.1350 | -0.1943 | -0.1857 | -0.1773 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 3/22/22 | 4/28/22 | 7/28/22 | 10/28/22 | 3/16/23 | 4/28/23 | 8/4/23 | 11/3/23 | 3/14/24 | - | - | - | - |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | 77.7 |
| Net Cash position 1 | - | - | - | - | - | 46.7 | 0.4 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | -0.9823 x |
| Free Cash Flow 1 | - | -61.2 | -68.3 | -74.8 | -61.2 | -65.7 | 30.1 | 55.9 |
| ROE (net income / shareholders' equity) | 20.2% | -25.4% | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 3.790 | 3.000 | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 1.89 | 1.71 | 2.64 | 1.24 | 0.8 | 1.34 | 1.55 | 1.62 |
| Capex / Sales | 1.7% | 11.06% | - | 31.49% | 5.41% | 16.05% | 2.54% | 2.45% |
| Announcement Date | 3/30/20 | 3/23/21 | 3/22/22 | 3/16/23 | 3/14/24 | - | - | - |
1CHF in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
2.15
CHF
Average target price
9.424
CHF
Spread / Average Target
+338.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -53.00% | 221M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ACIU Stock
- Financials AC Immune SA
